US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
BioPharma Dive15 日
FDA approves Amgen drug for tough-to-treat form of lung cancer
The Food and Drug Administration on Thursday granted accelerated approval to a new ... to gain FDA approval in cancer, and the first in small cell lung cancer. The FDA approved Imdelltra more than ...
FDA approves new drug for deadly lung cancer
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...
US FDA approves Amgen drug for small cell lung cancer
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
Yahoo Finance3 日
FDA approves Amgen’s interchangeable biosimilar Bkemv
The US Food and Drug Administration (FDA) has approved Amgen's Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare diseases.
Pharmaceutical Technology3 日
FDA approves Amgen’s interchangeable biosimilar Bkemv
Credit: Melnikov Dmitriy / Shutterstock.com. The US Food and Drug Administration (FDA) has approved Amgen‘s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for ...
Yahoo3 日
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar ... respectively. The FDA said that Bkemv is an interchangeable biosimilar, meaning that ...
KELO3 日
US FDA approves Amgen’s biosimilar to AstraZeneca’s rare blood disorder treatment
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen’s Bkemv, the first biosimilar to AstraZeneca’s rare blood disorder ... atypical hemolytic uremic syndrome – can cause anemia ...
Should you buy Amgen’s stock above $300?
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...